| Descriptor English: | Primaquine | ||||
| Descriptor Spanish: |
Primaquina
| ||||
| Descriptor Portuguese: | Primaquina | ||||
| Descriptor French: | Primaquine | ||||
| Entry term(s): |
Diphosphate, Primaquine Phosphate, Primaquine Primacin Primaquine Diphosphate Primaquine Phosphate |
||||
| Tree number(s): |
D03.633.100.810.050.650 |
||||
| RDF Unique Identifier: | https://id.nlm.nih.gov/mesh/D011319 | ||||
| Scope note: | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404) |
||||
| Allowable Qualifiers: |
AA analogs & derivatives AD administration & dosage AE adverse effects AG agonists AI antagonists & inhibitors AN analysis BL blood CF cerebrospinal fluid CH chemistry CL classification CS chemical synthesis EC economics HI history IM immunology IP isolation & purification ME metabolism PD pharmacology PK pharmacokinetics PO poisoning RE radiation effects SD supply & distribution ST standards TO toxicity TU therapeutic use UR urine |
||||
| Pharm Action: |
Antimalarials |
||||
| Registry Number: | MVR3634GX1 | ||||
| CAS Type 1 Name: | 1,4-Pentanediamine, N4-(6-methoxy-8-quinolinyl)- | ||||
| DeCS ID: | 11755 | ||||
| Unique ID: | D011319 | ||||
| NLM Classification: | QV 258 | ||||
| Documents indexed in the Virtual Health Library (VHL): | Click here to access the VHL documents | ||||
| Date Established: | 1966/01/01 | ||||
| Date of Entry: | 1999/01/01 | ||||
| Revision Date: | 2017/05/24 |
-
-
CHEMICALS AND DRUGS
Heterocyclic Compounds [D03]Heterocyclic Compounds
|
|
Primaquine
- Preferred
Primaquine Phosphate
- Narrower
Primacin
- Narrower
Primaquine Diphosphate
- Narrower
| Concept UI |
M0017573 |
| Scope note | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404) |
| Preferred term | Primaquine |
| Concept UI |
M0017575 |
| Preferred term | Primaquine Phosphate |
| Entry term(s) |
Phosphate, Primaquine |
| Concept UI |
M0475721 |
| Preferred term | Primacin |
| Concept UI |
M0329757 |
| Preferred term | Primaquine Diphosphate |
| Entry term(s) |
Diphosphate, Primaquine |
We want your feedback on the new DeCS / MeSH website
We invite you to complete a survey that will take no more than 3 minutes.
Go to survey